Link to Attana’s presentation at Stora Aktiedagen

December 2, Attana participated at Stora Aktiedagen where CEO Teodor Aastrup gave a company presentation followed by a Q&A session. 

The main focus of the presentation was to clarify Attana stands today, where the company is heading and the company’s action plan 2021. This included a presentation of the exciting projects planned for 2021, enabled by the upcoming rights issue.   

The full presentation and Q&A session can be found here. 

For more information, please contact: 
Niklas Carlsson, COO Attana AB 
e-mail: niklas.carlsson@attana.com  
Tel: + 46 738 676 762 

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated. 

About Attana 

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com